Angiodynamics Inc.

Company Overview

Business Model: AngioDynamics, Inc. is a diversified medical technology company focused on expanding treatment options and improving patient outcomes for cardiovascular disease and cancer diagnoses. The company designs, manufactures, and sells products and technologies, primarily minimally invasive, image-guided medical, surgical, and diagnostic devices. Its strategy emphasizes innovative research and development (R&D), clinical and regulatory pathway expansion, and customer-centric sales performance. Products are categorized into two segments: Med Tech and Med Device.

Market Position: The company operates in a highly competitive medical device industry characterized by rapid technological change, frequent product introductions, and evolving customer needs. AngioDynamics, Inc. competes based on product quality, clinical outcomes, ease of use, reliability, physician familiarity, and cost-effectiveness. It faces competition from a wide range of companies, from large manufacturers with extensive resources to smaller, specialized firms. The increasing influence of managed care, group purchasing organizations (GPOs), and integrated health delivery networks (IDNs) has intensified price competition.

Recent Strategic Developments:

• Divestitures and Discontinuations: In June 2023, AngioDynamics, Inc. completed the sale of its dialysis and BioSentry businesses to Merit Medical Systems, Inc. In February 2024, it sold its PICC and Midline businesses, including the C3 Wave tip location asset, to Spectrum Vascular. Concurrently, the company discontinued its RadioFrequency Ablation and Syntrax product lines. These actions are part of a strategy to transform into a high-growth, profitable medical technology company.
• Manufacturing Restructuring: In January 2024, AngioDynamics, Inc. announced a restructuring plan, modified in the second quarter of fiscal year 2025, to optimize its manufacturing efficiency and footprint. This involves maintaining a presence in Queensbury, NY for select products, customer service, logistics, shipping, quality, and regulatory operations, while shifting other manufacturing to outsourced third-party partners in various global locations (including the United States, Costa Rica, Latvia, Italy, Israel, and China). The restructuring is expected to be completed in the third quarter of fiscal year 2026 and is projected to generate $15.0 million in annual cost savings starting in fiscal year 2027.
• Product and Regulatory Milestones:
  • Auryon: Received CE mark approval in Europe and initiated the AMBITION BTK RCT and Registry to gather clinical evidence for treating below-the-knee lesions in critical limb ischemia patients.
  • NanoKnife: Received expanded FDA 510(k) clearance for prostate tissue ablation in December 2024. Secured CPT Category I Codes for Irreversible Electroporation (IRE) for prostate and liver lesions (effective January 2026) and for pancreas (effective January 2027).
  • AlphaVac: Published APEX-AV trial results demonstrating the safety and efficacy of the AlphaVac F1885 System and initiated the RECOVER-AV Clinical Trial in Europe.
• Capital Allocation: The Board of Directors approved a share repurchase program in July 2024, authorizing the repurchase of up to $15.0 million of outstanding common stock.
• Property Sales: In December 2024, the company entered into agreements to sell its manufacturing facilities in Queensbury, NY and Glens Falls, NY for $5.5 million and $1.2 million, respectively, while simultaneously entering into lease agreements for these properties.

Geographic Footprint: AngioDynamics, Inc. is headquartered in Latham, NY, U.S., with primary manufacturing operations historically in Queensbury, NY. The company sells its products in the United States primarily through a direct sales force and internationally through a combination of direct sales and distributor relationships. International sales accounted for 14% of total net sales in fiscal year 2025. The company intends to continue expanding into emerging and faster-growing international markets.

Financial Performance

Revenue Analysis

Profitability Metrics (FY2025):

• Gross Margin: 53.9%
• Operating Margin: -13.7%
• Net Margin: -11.6%

Investment in Growth (FY2025):

• R&D Expenditure: $26.2 million (9.0% of revenue)
• Capital Expenditures: $10.2 million (comprising $4.5 million in property, plant, and equipment additions and $5.7 million in placement and evaluation unit additions)
• Strategic Investments:
  • Auryon received CE mark approval in Europe and initiated the AMBITION BTK RCT and Registry.
  • NanoKnife received expanded FDA 510(k) clearance for prostate tissue ablation and secured CPT Category I Codes for Irreversible Electroporation (IRE) for prostate, liver, and pancreas.
  • AlphaVac published APEX-AV trial results and initiated the RECOVER-AV Clinical Trial in Europe.

Business Segment Analysis

Med Tech

Financial Performance (FY2025):

• Revenue: $126.7 million (+19.0% YoY)
• Operating Margin (Gross Margin): 62.0%
• Key Growth Drivers: Increased Auryon sales ($9.8 million), increased thrombus management platform sales ($10.9 million, driven by AngioVac, AlphaVac, and thrombolytic sales). NanoKnife sales remained consistent year over year, with increased disposable sales offset by decreased capital sales.

Product Portfolio:

• Auryon Atherectomy System: Designed for the treatment of peripheral arterial disease, including infrainguinal stenoses and occlusions, and in-stent restenosis (ISR). Features an optimized wavelength, short pulse width, and integrated aspiration.
• Thrombectomy: Includes the AlphaVac Mechanical Thrombectomy System, AngioVac venous drainage cannula and extracorporeal circuit, and catheter-directed thrombolytic devices such as the Uni-Fuse system, Uni-Fuse+ system, Pulse-Spray infusion system, and SpeedLyser infusion system.
• NanoKnife IRE Ablation System: Utilizes low energy direct current electrical pulses for the surgical ablation of soft tissue, including prostate tissue, by creating permanent pores in cell membranes.

Market Dynamics: This segment focuses on expanding treatment options for cardiovascular disease and cancer, driven by innovative R&D and clinical/regulatory pathway expansion.

Med Device

Financial Performance (FY2025):

• Revenue: $165.8 million (-16.0% YoY)
• Operating Margin (Gross Margin): 47.7%
• Key Growth Drivers: The decrease in sales was primarily due to the divestiture of PICCs and Midline products ($30.1 million impact), dialysis and BioSentry products ($0.7 million impact), and the discontinuation of the RadioFrequency Ablation product line ($2.2 million impact). This decline was partially offset by increased sales in Core products ($1.9 million) and Venous products ($0.9 million).

Product Portfolio:

• Peripheral Products (Interventional Devices): A comprehensive portfolio for minimally invasive procedures, including angiographic catheters (Soft-Vu Angiographic Catheters, Mariner Hydrophilic Catheters, Accu-Vu Sizing Catheters), diagnostic and interventional guidewires (ADx Peripheral Vascular Guidewire, NiT-Vu High Performance Micro Guidewires), Total Abscession Drainage Catheters, and Micropuncture Kits (Mini Stick MAX Coaxial Microintroducer Kits, Micro-Introducer Kits).
• Ports: Implantable devices for central venous administration of therapies and blood sampling, including SmartPort, SmartPort+, SmartPort Plastic, BioFlo Port, and Xcela Plus. Key technologies include BioFlo Endexo, Vortex, and PASV Valve Technology.
• Venous Insufficiency: VenaCure EVLT laser system for endovascular laser procedures to treat superficial venous disease, featuring diode laser hardware and procedure kits with NeverTouch tip fibers and the 400 Micron Perforator & Accessory Vein Ablation kit (PVAK).
• Microwave Ablation: Solero Microwave Tissue Ablation (MTA) System, indicated for the ablation of soft tissue during open procedures.
• Other Oncology Products: IsoLoc Endorectal Balloon and Alatus Vaginal Balloon Packing System, designed to assist in radiation therapy.

Market Dynamics: This segment has been significantly impacted by strategic divestitures and product line discontinuations, with efforts to drive growth in core interventional and venous product categories.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: In fiscal year 2025, AngioDynamics, Inc. repurchased 243,847 shares of common stock in the open market at an aggregate cost of $1.7 million under a Board-approved program.
• Dividend Payments: The company did not declare any cash dividends on its common stock during its last three fiscal years and does not anticipate paying any cash dividends for the foreseeable future.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: As of May 31, 2025, $13.3 million remained available for repurchase under the authorized share repurchase program.

Balance Sheet Position (as of May 31, 2025):

• Cash and Equivalents: $55.9 million
• Total Debt: $0 (no outstanding balance on the Revolving Facility)
• Net Cash Position: $55.9 million
• Debt Maturity Profile: The new Credit Agreement, entered into on May 28, 2025, provides for a $25.0 million secured revolving credit facility with a two-year maturity.

Cash Flow Generation (FY2025):

• Operating Cash Flow: -$10.1 million (cash used in operations)
• Free Cash Flow: Cash used in operations was $10.1 million, and capital expenditures totaled $10.2 million.

Operational Excellence

Production & Service Model: AngioDynamics, Inc. manufactures certain proprietary components and products, followed by assembly, inspection, testing, and packaging of finished products. This integrated approach aims to maintain quality control, ensure compliance with regulatory standards, and protect proprietary technology. The company utilizes custom-designed proprietary manufacturing and processing equipment.

Supply Chain Architecture: Key Suppliers & Partners:

• Manufacturing Partner: Biomerics (previously Precision Concepts) in Alajuela, Costa Rica, manufactures, stores, and handles certain products. This facility is registered with the FDA and certified to ISO 13485 standards.
• Third-Party Manufacturers: The company relies on other third-party manufacturers for certain products and is expanding its outsourced manufacturing model to various locations globally, including the United States, Costa Rica, Latvia, Italy, Israel, and China.

Facility Network:

• Corporate Headquarters: Latham, NY (39,000 sq. ft., leased)
• Manufacturing: Queensbury, NY (135,000 sq. ft., leased), Glens Falls, NY (21,000 sq. ft., leased). Both facilities are registered with the FDA and certified to ISO 13485 standards and the Medical Device Single Audit Program (MDSAP).
• Research & Development: Marlborough, MA (8,400 sq. ft., leased), Rehovot, IL (4,300 sq. ft., leased).
• Distribution: Queensbury, NY (58,000 sq. ft., leased).

Operational Metrics:

• Backlog: $0.3 million as of May 31, 2025, down from $1.3 million at May 31, 2024. The company aims to maintain sufficient inventory to ship products within 24-48 hours of order receipt.
• Restructuring Cost Savings: The modified manufacturing restructuring plan is expected to generate $15.0 million in annual cost savings starting in fiscal year 2027.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Primarily utilized in the United States through a direct sales force.
• Channel Partners: International sales are mainly conducted through distributor relationships, which accounted for approximately 74% of international revenues in fiscal year 2025.

Customer Portfolio: End Users: The company focuses its sales and marketing efforts on interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses.

• Customer Concentration: No single customer represents more than 10% of total consolidated net sales.

Geographic Revenue Distribution (FY2025):

• United States: 85.8% of total revenue ($251.0 million)
• International: 14.2% of total revenue ($41.5 million)
• Growth Markets: AngioDynamics, Inc. intends to continue its expansion into emerging and faster-growing markets outside the U.S.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The medical device industry is highly competitive, characterized by rapid technological advancements, frequent product introductions, and evolving customer requirements. Product life cycles are relatively short due to continuous innovation. The industry is also experiencing consolidation, leading to companies with greater scale and market power. Key Trends: The market is increasingly influenced by value-based purchasing by healthcare providers, consolidation among healthcare providers, an increased role of consumers in healthcare decision-making, and an aging population. These trends, coupled with declining reimbursement rates, place increased emphasis on cost-effective medical devices and therapies.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: Boston Scientific Corporation; Cook Medical; Medical Components, Inc. (MedComp); TeleFlex Medical; Becton Dickinson; Medtronic; Merit Medical; Terumo Medical Corporation; Johnson and Johnson; Philips Healthcare; Stryker Corporation; Penumbra, Inc.; Varian Medical Systems; Abbott Laboratories and Total Vein Systems.

Emerging Competitive Threats: New market entrants, disruptive technologies, and alternative non-surgical therapies (e.g., from pharmaceutical companies).

Competitive Response Strategy: AngioDynamics, Inc. aims to maintain its competitive advantage by developing or acquiring scientifically advanced technology, applying technology cost-effectively across product lines, attracting and retaining skilled personnel, obtaining patent protection, securing required regulatory and reimbursement approvals, efficient manufacturing, and effective marketing.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: Intense competition, rapid technological change, and industry consolidation may lead to loss of market share and pricing pressure. The inability to adapt to changing customer needs or to develop superior products could adversely affect revenue.
• Technology Disruption: The market for medical devices is characterized by short product life cycles. Failure to successfully develop, acquire, or market new products, generate satisfactory clinical results, or provide sufficient economic value could limit growth. The future prospects of high-growth products like NanoKnife, AngioVac, AlphaVac, and Auryon rely on continued market development and clinical data generation.
• Reimbursement: The ability of customers to obtain adequate reimbursement from governmental programs, private insurance, and managed care plans is critical. Changes in healthcare reforms or adverse reimbursement decisions could limit demand and impact pricing flexibility.

Operational & Execution Risks

• Supply Chain Vulnerabilities: Dependence on single and limited source suppliers for key products, raw materials, and components poses risks of delivery delays, shortages, and supply interruptions. The planned shift to a partially outsourced manufacturing model introduces additional risks, including reduced control over manufacturing, potential product quality issues, price fluctuations, and regulatory or operational disruptions.
• Geographic Concentration: International sales expose the company to risks from currency fluctuations, trade restrictions, tariffs, U.S. export controls, non-U.S. tax laws, shipping delays, and economic/political instability.
• Capacity Constraints: The ongoing manufacturing restructuring to optimize efficiency and footprint carries execution risks, including potential delays, higher-than-anticipated costs, and business disruptions.
• Labor Shortages: The ability to attract and retain highly qualified personnel, including managerial, sales, and technical staff, is crucial. Intense competition for sales personnel could lead to significant turnover and adversely affect business and revenue.
• Disasters: Manufacturing facilities in Queensbury, NY, Glens Falls, NY, and third-party locations are vulnerable to natural disasters, labor strikes, political unrest, or pandemics, which could disrupt production for extended periods.

Financial & Regulatory Risks

• Market & Financial Risks: Macro-economic fluctuations (e.g., recession, high inflation, international conflicts) could negatively affect customer demand and increase operational costs. The need for additional capital for business expansion or acquisitions, coupled with potential disruptions in capital markets, could lead to increased indebtedness and restrictive covenants.
• Regulatory & Compliance Risks: The company is subject to extensive federal, state, and international laws and regulations (e.g., FDA, QSR, MDR, Anti-kickback Statute, False Claims Act, FCPA, HIPAA, GDPR). Non-compliance or allegations thereof could result in fines, injunctions, product recalls, marketing restrictions, and civil or criminal prosecution. Obtaining and maintaining regulatory clearances and approvals is costly, time-consuming, and subject to increasing scrutiny.
• Product Liability: The design, manufacture, and marketing of medical devices entail inherent product liability risks. The company is defending approximately 162 Port Product Claims consolidated in multidistrict litigation. Existing product liability insurance coverage ($10 million per claim, $10 million aggregate, with a $0.5 million self-insured retention per occurrence and $2 million aggregate) may not be adequate to cover all potential losses.

Geopolitical & External Risks

• Geopolitical Exposure: Operations in international markets, including component sourcing and manufacturing in China, expose the company to economic, political, and legal developments in these regions.
• Trade Relations: Changes in international trade policy, treaties, and tariffs (e.g., between the U.S. and China) could increase costs, negatively impact sales, or necessitate operational modifications.
• Sanctions & Export Controls: Compliance with U.S. economic sanctions regulations (OFAC, BIS) is complex and constantly changing. Business dealings in certain sanctioned countries (e.g., Iran, which generated $0.6 million in revenue in FY2025) carry a heightened risk of violations.
• Global Conflicts: Geopolitical developments, such as the Russia-Ukraine and Israel-Hamas conflicts, are sources of uncertainty that may disrupt global or regional markets, supply chains, and operations.
• Environmental, Social and Governance (ESG) & Climate Change: Increasing focus on corporate ESG practices and climate change risks could lead to reduced demand, increased costs, investigations, or litigation if the company's practices are deemed inadequate or if adverse weather patterns impact operations.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas: AngioDynamics, Inc. focuses its R&D efforts on expanding treatment options for cardiovascular disease and cancer, particularly through minimally invasive, image-guided procedures. Innovation Pipeline: The company's growth strategy relies on the continuous introduction of new and innovative products and enhancements to existing products. This is achieved through internal product development, technology licensing, strategic alliances, and acquisitions. Recent examples include advancements in Auryon, AlphaVac, and NanoKnife systems.

Intellectual Property Portfolio:

• Patent Strategy: AngioDynamics, Inc. owns an extensive portfolio of patents and patent applications in the United States and various foreign countries, along with exclusive licenses to third-party patents. The company actively monitors third-party proprietary rights to inform its IP strategy, avoid infringement, and identify licensing opportunities.
• IP Litigation: The company operates in an industry prone to patent litigation. In March 2024, AngioDynamics, Inc. and Becton, Dickinson and Company (BD) entered into a settlement agreement to resolve ongoing patent litigations related to port and catheter products, involving cross-licensing and a one-time lump sum payment, plus minimum annual payments and potential additional payments.

Technology Partnerships: The company engages in technology licensing and strategic alliances as part of its product development and growth strategy.

Leadership & Governance

Executive Leadership Team

Board Composition: The Board of Directors is actively engaged in the company’s enterprise risk management (ERM) program and oversees cybersecurity strategies, systems, and controls. The Audit Committee discusses policies related to risk assessment and management, including information technology and security systems. The Board receives regular updates on the company’s cybersecurity risk management program from the Senior Vice President, Information Technology.

Human Capital Strategy

Workforce Composition:

• Total Employees: As of May 31, 2025, AngioDynamics, Inc. had approximately 675 full-time employees.
• Skill Mix: The company prioritizes attracting, developing, engaging, and retaining high-performing talent in positions critical to long-term growth, including technical, operational, marketing, sales, research and development, and management roles.

Talent Management:

• Acquisition & Retention: The company's ability to recruit and retain talent is influenced by its culture, compensation and benefits, talent development programs, career opportunities, recognition, and work environment.
• Employee Value Proposition: AngioDynamics, Inc. is committed to fostering a diverse and inclusive culture that promotes a welcoming, respected, and valued environment for employees, making employment decisions without regard to protected characteristics.

Diversity & Development:

• Culture & Engagement: The company places high importance on informed and engaged employees, utilizing frequent and transparent communication methods such such as video, written communications, town hall meetings, and its company intranet.

Environmental & Social Impact

Environmental Commitments: Climate Strategy: AngioDynamics, Inc. is subject to federal, state, and local laws and regulations governing the use, generation, manufacture, storage, and disposal of hazardous substances, as well as occupational health and safety. The company maintains safety, training, and maintenance programs to ensure compliance. New laws or regulations adopted in response to climate change could increase energy and transportation costs, as well as the costs of certain raw materials and components.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: The company experiences seasonal fluctuations in revenue, partly due to the elective nature of some medical procedures utilizing its products.
• Economic Sensitivity: AngioDynamics, Inc.'s business and financial performance are influenced by broader economic conditions, including recessions, high inflation, international conflicts, and pandemic illnesses, which can impact consumer confidence, spending patterns, and customer orders.

Planning & Forecasting: Macroeconomic conditions make it challenging for the company to accurately forecast and plan future business activities.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations: AngioDynamics, Inc.'s products are subject to extensive regulation by the United States Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (FDCA), requiring 510(k) clearance or Premarket Approval (PMA). Manufacturing processes must comply with the FDA’s Quality System Regulation (QSR). The company is also subject to regulations regarding adverse event reporting and prohibitions against promoting products for unapproved ("off-label") uses. International Compliance: Sales in the European Union and other countries require compliance with various regulatory regimes, including the Medical Device Regulation (MDR) for the EU, which mandates CE Mark approval. MDR compliance involves extensive clinical evaluations, biocompatibility, bench testing, and can lead to extended certification timeframes. Similar regulations exist in Canada, Japan, China, and Brazil.

Trade & Export Controls:

• Export Restrictions: The company must comply with FDA export requirements for unapproved devices.
• Sanctions Compliance: AngioDynamics, Inc. is subject to U.S. economic sanctions laws and regulations administered by the U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC) and the Bureau of Industry and Security (BIS). In fiscal year 2025, the company generated $0.6 million in revenue from sales to distributors doing business in Iran.

Legal Proceedings: AngioDynamics, Inc. is involved in various legal proceedings, including patent infringement and product liability matters. A material settlement agreement was reached in March 2024 with Becton, Dickinson and Company (BD) to resolve ongoing patent litigations. The company is also defending approximately 162 product liability claims (Port Product Claims) consolidated in the U.S. District Court for the Southern District of California.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate (FY2025): The company reported an income tax benefit of 0.1%.
• Effective Tax Rate (FY2024): The company reported an income tax benefit of 3.8%.
• Rate Drivers: The effective tax rates differ from the U.S. federal statutory rate (21%) primarily due to the impact of a valuation allowance, foreign taxes, non-deductible permanent items, goodwill impairment, and stock-based compensation.
• Net Operating Loss Carryforwards: As of May 31, 2025, U.S. Federal net operating loss carryforwards (after IRC Section 382 limitations) totaled $135.6 million, with $37.1 million expiring between 2030 and 2032, and $98.5 million indefinitely. State net operating loss carryforwards amounted to $23.9 million, expiring between 2030 and 2043. Israel tax net operating losses of $19.2 million can be carried forward indefinitely.
• Valuation Allowance: A full valuation allowance has been recorded on the company's U.S. net deferred tax assets as of May 31, 2025, due to not yet attaining a sustained level of profitability and objectively verifiable negative evidence outweighing positive evidence.
• Geographic Tax Planning: The company intends to indefinitely reinvest the unremitted foreign earnings of its subsidiaries.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: AngioDynamics, Inc. maintains product liability insurance coverage with a limit of $10.0 million per claim and an annual aggregate policy limit of $10.0 million. This coverage is subject to a self-insured retention of $0.5 million per occurrence and $2.0 million in the aggregate. The policy covers claims of bodily injury and property damage from products sold or manufactured by the company.